Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER

Retrospective analyses of NSABP B20 and SWOG 8814 showed a large benefit of chemotherapy in patients with ER-positive tumors and high OncotypeDX Recurrence Score (RS≥31). However, it might be possible that both studies may be contaminated by non-luminal tumors, especially in high-risk RS group. We c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2015-01, Vol.26 (1), p.70-74
Hauptverfasser:	Sun, Z., Prat, A., Cheang, M.C.U., Gelber, R.D., Perou, C.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use basal-like Biomarkers, Tumor Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology breast tumor Chemotherapy, Adjuvant Computer Simulation ER-positive Female Her2-enriched Humans luminal A luminal B Neoplasm Recurrence, Local - drug therapy OncotypeDX Recurrence Score PAM50 Receptors, Estrogen - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!